Pidotimod for the prevention of acute respiratory infections in healthy children entering into daycare: A double blind randomized placebo-controlled study.
Acute respiratory tract infections (ARTIs) are very common in pediatric age and reach a peak in the first 4 years of life, especially in children attending daycare. Pidotimod, a synthetic immunostimulant, may reduce the incidence of ARTIs in children with predisposing risk factors. Nevertheless studies on healthy children are presently lacking. We performed a double-blinded randomized placebo-controlled trial study to assess the efficacy of Pidotimod in a population of 3-year-old healthy children who just entered kindergarten. The main outcome was the incidence of respiratory infections in this population and the secondary outcome was the prescription of antibiotics. The study group consisted of healthy 3-year-old children who had not yet attended day-care centers. Patients were enrolled by a convenience sample of 17 family pediatricians (FP). Children were randomized to receive either Pidotimod 400 mg per os or placebo twice daily for the last 10 days of each month from October 2013 to April 2014. Any time a child presented to his/her FP with fever and ARTI was diagnosed, clinical and therapeutic data were collected. A total of 800 children were pre-screened, 733 did not meet the inclusion criteria and 10 refused to participate. Of the 67 eligible subjects, 57 were successfully enrolled within the study recruitment period and randomized to receive Pidotimod (n = 29) or placebo (n = 28). Eight children were lost to follow-up. In the final analysis were thus included 24 children who received Pidotimod and 25 who received placebo. The incidence rate ratio for respiratory infections was 0.78 (95%CI 0.53 to 1.15, p = 0.211) for Pidotimod vs. placebo. The corresponding risk ratio for antibiotic usage was 0.56 (95%CI 0.27 to 1.16, p = 0.120). In our trial, Pidotimod did not prove to be statistically superior to placebo for the prevention of ARTI in a population of healthy children who entered kindergarten. However, Pidotimod showed some potential as a means for reducing antibiotic usage in these children.
Department of Pediatrics, Ospedale dei Bambini V.Buzzi, University of Milan, Milan, Italy.
Chiara
C
Mameli
Center for Research and Education of Family Pediatricians (CESPER), Padova, Italy.
Angela
A
Pasinato
Pediatric Society of Primary Health Care (SICuPP), Milan, Italy.
Marina
M
Picca
Clinical Epidemiology Unit, Liver Research Center, Basovizza, Trieste, Italy.
Giorgio
G
Bedogni
Department of Pediatrics, Luigi Sacco Hospital, University of Milan, Milan, Italy.
Stefania
S
Pisanelli
Department of Pediatrics, Ospedale dei Bambini V.Buzzi, University of Milan, Milan, Italy. Electronic address: gianvincenzo.zuccotti@unimi.it.
Gian Vincenzo
GV
Zuccotti
D000208:Acute Disease; D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use*; D002656:Child Day Care Centers; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007114:Immunization; D015994:Incidence; D007223:Infant; D008297:Male; D011761:Pyrrolidonecarboxylic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012141:Respiratory Tract Infections / Q000517:prevention & control*; D040242:Risk Reduction Behavior; D053778:Thiazolidines / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D053778:Thiazolidines; C064893:pidotimod; D011761:Pyrrolidonecarboxylic Acid
Children; Immunostimulant; Kindergarten; Pidotimod; Respiratory infections